Morgan Stanley lowered the firm’s price target on AbbVie (ABBV) to $224 from $231 and keeps an Overweight rating on the shares following the “surprising” negative emraclidine Phase 2 update. The firm, which notes it removed emraclidine from its model and raised its Cobenfy estimates for Bristol Myers (BMY), so 2033 total revenue goes up 7%, adds that “bottom line is this does not change the overall rev/EPS growth trajectory for either stock.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure
- AbbVie price target lowered to $215 from $226 at Citi
- Cigna drops pursuit of Humana: Morning Buzz
- Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
- AbbVie under pressure as schizophrenia drug fails two trials